Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
作者信息
Ravandi F, Arana Yi C, Cortes J E, Levis M, Faderl S, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce S, Brandt M, Pratz K, Luthra R, Andreeff M, Kantarjian H
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Division of Hematological Malignancies, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.
出版信息
Leukemia. 2014 Jul;28(7):1543-5. doi: 10.1038/leu.2014.54. Epub 2014 Feb 3.
Abstract
摘要
相似文献
1
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Leukemia. 2014 Jul;28(7):1543-5. doi: 10.1038/leu.2014.54. Epub 2014 Feb 3.
2
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
J Clin Oncol. 2010 Apr 10;28(11):1856-62. doi: 10.1200/JCO.2009.25.4888. Epub 2010 Mar 8.
3
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):361-6. doi: 10.1016/j.clml.2011.06.007.
4
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Leuk Lymphoma. 2013 Apr;54(4):760-6. doi: 10.3109/10428194.2012.737917. Epub 2012 Nov 15.
5
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.
6
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Lancet Haematol. 2019 Sep;6(9):e480-e488. doi: 10.1016/S2352-3026(19)30114-0. Epub 2019 Aug 7.
7
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):241-242. doi: 10.1016/j.clml.2016.10.002. Epub 2017 Jan 11.
8
Escalated anthracycline dose in adult AML.
Lancet Oncol. 2017 May;18(5):e253. doi: 10.1016/S1470-2045(17)30277-2. Epub 2017 Apr 13.
9
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
J Clin Oncol. 2013 Sep 1;31(25):3110-8. doi: 10.1200/JCO.2012.46.4990. Epub 2013 Jul 29.
10
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):e13-7. doi: 10.1016/j.clml.2013.08.005. Epub 2013 Oct 19.
引用本文的文献
1
Therapeutic biomarkers in acute myeloid leukemia: functional and genomic approaches.
Front Oncol. 2024 Feb 12;14:1275251. doi: 10.3389/fonc.2024.1275251. eCollection 2024.
2
A Review of Childhood Acute Myeloid Leukemia: Diagnosis and Novel Treatment.
Pharmaceuticals (Basel). 2023 Nov 15;16(11):1614. doi: 10.3390/ph16111614.
3
How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?
Cancer Drug Resist. 2023 Apr 28;6(2):223-238. doi: 10.20517/cdr.2022.130. eCollection 2023.
4
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Blood Adv. 2023 Sep 12;7(17):4950-4961. doi: 10.1182/bloodadvances.2023010392.
5
New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia.
Haematologica. 2023 Feb 1;108(2):321-341. doi: 10.3324/haematol.2022.280798.
6
FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile.
Onco Targets Ther. 2023 Jan 19;16:31-45. doi: 10.2147/OTT.S236740. eCollection 2023.
7
Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein.
ACS Med Chem Lett. 2022 Nov 4;13(12):1885-1891. doi: 10.1021/acsmedchemlett.2c00402. eCollection 2022 Dec 8.
8
Treatment options for acute myeloid leukemia patients aged <60 years.
Front Oncol. 2022 Oct 5;12:897220. doi: 10.3389/fonc.2022.897220. eCollection 2022.
9
The Role of Nutrition in Primary and Secondary Prevention of Cardiovascular Damage in Childhood Cancer Survivors.
Nutrients. 2022 Aug 11;14(16):3279. doi: 10.3390/nu14163279.
10
High-Risk Acute Myeloid Leukemia: A Pediatric Prospective.
Biomedicines. 2022 Jun 14;10(6):1405. doi: 10.3390/biomedicines10061405.
本文引用的文献
1
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
J Clin Oncol. 2013 Sep 1;31(25):3110-8. doi: 10.1200/JCO.2012.46.4990. Epub 2013 Jul 29.
2
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Blood. 2012 May 31;119(22):5133-43. doi: 10.1182/blood-2011-06-363960. Epub 2012 Feb 24.
3
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.
Cancer. 2011 May 15;117(10):2145-55. doi: 10.1002/cncr.25670. Epub 2010 Nov 29.
4
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
Blood. 2011 Mar 24;117(12):3294-301. doi: 10.1182/blood-2010-08-301796. Epub 2011 Jan 26.
5
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23.
6
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
J Clin Oncol. 2010 Apr 10;28(11):1856-62. doi: 10.1200/JCO.2009.25.4888. Epub 2010 Mar 8.
7
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29.
8
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443.
9
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood. 2005 Feb 1;105(3):986-93. doi: 10.1182/blood-2004-05-1846. Epub 2004 Sep 30.
10
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Blood. 2004 Dec 15;104(13):4202-9. doi: 10.1182/blood-2003-10-3381. Epub 2004 Aug 10.
Zotero 插件